Search Results
Showing Results for South Africa
In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.
Topline results from phase III PURPOSE 1 trial (NCT04994509) demonstrate the twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women. Â
The expansion of HIV treatment access during the past two decades, particularly in low- and middle-income countries, stands as a significant accomplishment in the field of public health.1Â Currently, there are an estimated 30 million people on antiretroviral treatment for HIV ...
Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key ...
It was a pleasure to meet with Yvette Raphael, patient advocate in HIV and Executive Director of Advocacy for Prevention of HIV and AIDS (APHA), South Africa, to share her perspective on the barriers of women and other populations being ...
It was a pleasure to meet with Yvette Raphael, patient advocate in HIV and Executive Director of Advocacy for Prevention of HIV and AIDS (APHA), South Africa, to share her perspective on evolving research, especially the use of bNAbs for ...
It was a pleasure to meet with Yvette Raphael, patient advocate in HIV and Executive Director of Advocacy for Prevention of HIV and AIDS (APHA), South Africa, to share her perspective on disparities in HIV care and treatment. Yvette discusses ...
Neonatal sepsis is often a result of pathogenic infection in a hospital setting and is a high risk for mortality especially in low and middle income countries. We caught up with Dr. Michelle Clements (University College London, London, UK) to ...
It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting ...
While the global commitment to treating HIV has saved countless lives, efforts to prevent new HIV infections have not been so fruitful. The annual number of new HIV infections among adults worldwide has barely changed over the past 5 years, with ...
Welcome to the first issue of touchREVIEWS in Infectious Diseases, which aims to publish topical interviews, reviews, editorials, case studies and original research in the field of infectious diseases. The development of antibiotics and vaccines remain among the greatest accomplishments ...
Extrapulmonary tuberculosis (TB) – i.e. when the disease presents outside of the lungs – has existed since antiquity, as evidenced by studies in paleopathology.1 The skeleton is a common site for extrapulmonary TB, but isolated rib TB is rare.2 One in 50 ...
Recurrent vulvovaginal candidiasis is associated with significant disease, financial and quality-of-life burdens.1 Fluconazole has been used since 2004 for symptom control; however, its use is limited by the development of resistance and a high rate of vulvovaginal candidiasis recurrence after therapy ...
The HVTN 702 phase 2b-3 HIV-1 vaccine trial assesses the preventive vaccine efficacy, safety, and tolerability of ALVAC/gp120 + MF59 vaccines in South African adults. Dr Zoe Moodie (Fred Hutchinson Cancer Center, Seattle, WA, USA) joins touchINFECTIOUSDISEASES to discuss the aims ...
There are number of challenges in the development of a HIV vaccine. Dr Zoe Moodie (Fred Hutchinson Cancer Center, Seattle, WA, USA) joins touchINFECTIOUS DISEASES to discuss the challenges and the current status in the development of HIV vaccines. The ...
Novavax's COVID-19 vaccine, Nuvaxovid, has been authorised for use in the UK for those aged 18 and over. Prof. Paul Heath (St George's, University of London, London, UK) kindly met with touchINFECTIOUS DISEASES to discuss the Novavax vaccine (Nuvaxovid), the clinical ...
It was a great pleasure to meet with Prof. Paul Heath (St George's, University of London, London, UK) to discuss the findings from the Novavax program of clinical trials evaluating the safety and efficacy of NVX-CoV2373 across the US, South ...
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the the health burden of HIV among young women and adolescent girls in Africa, and the need for pre-exposure prophylaxis. The abstract entitled: ‘Adherence ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
